Cell and gene therapy products
Cell and gene therapy products
Cell and gene therapy products
Cell and gene therapy products

EXUMA is a clinical-stage biotechnology company
developing gene vector delivery solutions and
products to improve patient access to innovation in
the cell and gene therapy space.

Our technologies enable the development of great medicines without the limitations of cell therapy.
rPOC Subcutaneous platform

rPOC SC Platform

A dedicated synthetic lymph node as a CAR production line

EXUMA’s rPOC Subcutaneous (SC) platform has been designed to optimize efficacy and safety, while eliminating the need for lymphodepleting chemotherapy. rPOC SC autologous cell therapies have the potential for administration in settings away from tertiary care.

T cell targeted lentivector function

GCAR Platform

Reprograming your own lymph nodes

EXUMA is advancing the technology underpinning rPOC to enable in vivo CAR-T therapy.

Technologies

Addressing the Different Limitations of Cell Therapy

EXUMA’s CD3-Targeted lentivector
CD3-Targeted LV

EXUMA’s CD3-Targeted lentivector selectively targets and loads lymphocytes ex vivo or in vivo for subsequent transduction and all in vivo expansion

fitness driver transgenes by Exuma
FITNESS DRIVER

EXUMA’s FITNESS DRIVER transgene encodes a semi-synthetic protein identified for optimization of effector cell stemness, proliferation, persistence, and cytotoxicity with all in vivo expansion without the need for preparative lymphodepleting chemotherapy

cell therapy companies
tumor metabolism illustration
Tumor Metabolism Regulated (TMR) CARs

EXUMA’s TMR CARs significantly expands the universe of targetable antigens beyond those unique to solid tumors

EXUMA Synthetic CAR ligand
Synthetic CAR Ligands (SCL)

EXUMA’s Synthetic CAR ligand enables expansion and persistence with administration of an off-the-shelf mRNA encoding a CAR activating ligand

Pipeline

EXUMA Biotech is discovering and developing cell and gene therapies for autoimmune disease and cancer.